Home Featured Page 16

Featured

Latest

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr....

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin...

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

PS 25 Morning Show – Day Three

When it Comes to Psychedelic Access, It’s the Messenger, Not the...

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy...

Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson...

1...151617...306 Page 16 of 306

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr....

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin...

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

PS 25 Morning Show – Day Three

PS 25 Morning Show – Day Two

When it Comes to Psychedelic Access, It’s the Messenger, Not the...

PS 25 Morning Show – Day One

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy...

Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson...

EDITOR PICKS

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY